GORX Geopharma (MM)

GeoPharma, Inc. (Nasdaq:GORX) (the "Company") announced today that the FDA Office of Compliance has completed the evaluation of its Largo, Florida manufacturing facility dedicated to the production of Cephalosporin antibiotics and has indicated, based on the adequacy of the Company's written response, that it is acceptable to manufacture upon FDA approval of its Cephalexin ANDA.

Commenting on the milestone GeoPharma CEO Mihir Taneja stated, "The approval of this facility has been long anticipated. We are so pleased to have finally gained the endorsement of our facility by the FDA and we look forward to the related Cephalexin ANDA approval during the fiscal year ending March 31, 2011. We have made dramatic in roads with regards to our relationships in these areas and believe the plant approval and pending ANDA approval will be beneficial to the future of the Company. In this morning's conference call we will be discussing the company financials as well as the plant approval and other pertinent information related to our business."

A conference call has been scheduled for Tuesday, March 2, 2010 at 11 a.m. Eastern time. The conference call will be hosted by GeoPharma, Inc. CEO Mihir Taneja and Sr. VP/CFO Carol Dore-Falcone. Participants may dial in 15 minutes before the call is set to begin to register. The dial in number for participants is 1-408-337-0124. The Conference Confirmation code is 60291243. 

A replay of the call will be available from 2 p.m. ET on March 2nd, through Tuesday, March 16th. The Replay of the call may be heard by dialing 706-645-9291. The Replay Pass Code is 60291243. Participants may also choose to listen to the call via webcast through the link in the events and presentations section of the Investor Relations page of the GeoPharma website located at http://www.geopharmainc.com.  

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in: Pharmaceuticals, Contract Manufacturing, and Medical devices. The Pharma divisions specialize in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing division manufactures and packages generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

For further information visit the GeoPharma website at www.geopharmainc.com.

The GeoPharma, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5384

FORWARD-LOOKING STATEMENTS

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

CONTACT: GeoPharma, Inc.

Carol Dore-Falcone, Sr. VP/CFO

1-727-544-8866, ext. 227

IR@GeoPharmainc.com